QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

MANE

QT68Veradermics, Incorporated
NYSE·Healthcare·Biotechnology·USA
Latest market price
93.87
+2.00+2.18%
OverviewShort InterestFilings
MANEQT68Veradermics, Incorporated·NYSE
OverviewShort InterestFilings
93.87+2.18%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own-
Shs Outstand41.78M
Perf Week-0.56%
Market Cap3.84BForward P/E-EPS next Y-2.69Insider Trans-Shs Float-Perf Month-6.20%
Enterprise Value3.67BPEG-EPS next Q-0.67Inst Own-Short Float-Perf Quarter64.94%
Income-61411328.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y-
Sales-P/B8.75EPS next Y9.82%ROA-13.73%Short Interest-Perf YTD-
Book/sh-2.90P/C-EPS next 5Y-ROE-95.40%52W High-Perf Year-
Cash/sh3.40P/FCF-EPS past 3/5Y-ROIC-15.02%52W Low-Perf 3Y-
Dividend Est.-EV/EBITDA-68.07Sales past 3/5Y-Gross Margin0.00%Volatility4.77% 4.77%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-Oper. Margin0.00%ATR (14)6.94Perf 10Y-
Dividend Ex-Date-Quick Ratio59.12Sales Y/Y TTM-Profit Margin0.00%RSI (14)47.90Recom2.00
Dividend Gr. 3/5Y-Current Ratio59.12EPS Q/Q-SMA20-3.46%Beta1.01Target Price105.50
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA500.08%Rel Volume1.39Prev Close91.87
Employees21LT Debt/Eq0.07EarningsSep 02SMA200-Avg Volume587.96KPrice93.87
IPO DateFeb 04, 2026Option/ShortNo / YesEPS/Sales Surpr.58.05% -Net Debt/EBITDA3.12Volume816,890Change2.18%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-02-26InitiatedNeedhamBuy$136
Mar-02-26ReiteratedJefferies$75
Latest News
Jun-17-26
Jun-17-2612:02AM
LifeSci Capital Initiates Coverage of Veradermics (MANE) with Outperform RecommendationFintel
Jun-16-26
Jun-16-2612:51PM
LifeSci Capital Initiates Coverage On Veradermics with Outperform Rating, Announces Price Target of $135Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
Total Revenue
000
Cost of Goods Sold Incl. D&A
000
Gross Profit
000
Selling, General and Administrative Excl. Other1032
Research and Development622315
Other Operating Expense010
Operating Income-72-27-17
Interest Expense010
Unusual Expense
———
Non-Operating Income (Expense)-2-1-1
Net Income Before Taxes-70-26-16
Income Taxes
000
Consolidated Net Income-70-26-16
Net Income From Continuing Operations-70-26-16
Net Income-70-26-16
EPS (Recurring)-2.38-0.14-0.08
EPS (Basic, Before Extraordinaries)-2.38-0.14-0.08
EPS (Diluted)-2.38-0.14-0.08
EBITDA-70-26-16
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding35201201
Market Capitalization
———
Operating Lease Expense
———
Insider Trading Volume
$109.67$103.15$96.63$90.12$83.60● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR